- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02994043
Alcohol, Inflammation, and Mindfulness Study (AIM)
Dismantling MBRP: Identifying Critical Neuroimmune Mechanisms of Action.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study was designed to evaluate the effect of two outpatient, individually-administered, psychosocial interventions (Relapse Prevention vs. Mindfulness-Based Relapse Prevention). Participants are recruited via mass media advertisements, flyers, and local outreach to clinical providers that do not address substance use. We will recruit 226 individuals. Our previous experience with clinical trials, as well as the experience of our research team members with these interventions support the feasibility of recruiting approximately 50 patients per year. This sample size provides adequate statistical power for the research questions undertaken.
Participants are screened over the telephone and invited into the laboratory for a baseline assessment. Immediately after the baseline assessment, they are randomized to a therapist and then to a treatment condition. At the end of each year, the distribution of participants across conditions and therapists are evaluated for imbalances. If attrition has resulted in an imbalance across conditions, the randomization procedure will be adjusted to ensure equal numbers of participants in RP and MBRP.
Within a week of completing the baseline assessments, participants are seen by their individual therapist for a motivational interviewing, goal-setting session. After the goal-setting session, the eight-session MBRP or RP treatments are administered. To ensure that therapists adhere to treatment manuals, a checklist is provided consisting of the primary content addressed each session (four to seven primary content pieces each session). Further, questionnaires assessing mindfulness practice and facets of mindfulness (e.g., being nonjudgmental, nonreactive) are administered at each assessment. At the most recent RPPR, these questionnaires validated that participants in the MBRP condition were increasing in some facets of mindfulness during treatment (and up to three months after treatment).
We estimate that the completion of assessments and procedures across the duration of the trial, excluding therapy sessions, will total about 15 hours of time. To compensate subjects for their time and travel costs, each subject will be paid $300 if they complete all sessions.
We will conduct extensive analyses of any attrition encountered in the project to determine bias. However, note that in each of the analyses described herein, we will have the capability of using modern approaches to the handling of missing data including full information maximum likelihood estimation of missing data within Proc Mixed in SAS and within EQS.
The distributional properties of all continuously scaled variables will be examined for skewness and kurtosis to determine the need for normalizing transformations or for alternations to our analysis plan (i.e., generalized estimating equations or robust estimation) prior to the primary analyses.
To confirm the validity of random assignment, pretest equivalence of the two treatment conditions across demographics, drinking history, smoking, and all other baseline measures will be assessed via t-tests on continuous items and c2 tests of categorical items. We will use the Bonferroni approach to correct for alpha inflation with a familywise alpha of .05. Any variables on which the two groups are unequal at pretest will be covariates in all further analyses.
Attrition analyses will be conducted after each follow-up data collection effort to provide assurance that differential attrition by treatment condition has not occurred. Following previously published procedures, a series of ANOVAs of treatment (MBRP versus RP) X retention (retained, not retained) will be conducted on continuous baseline measures. Significant treatment X retention interactions identify measured variables on which differential attrition may have occurred. The logit model analog procedure will be applied to categorical baseline measures to test for differential attrition on categorical variables such as gender and ethnicity. We will conduct these analyses to assure that differential attrition by treatment condition does not account for any of the effects of the treatments.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80045
- University of Colorado Denver
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have a primary Diagnostic Statistical Manual-V (DSM-V) diagnosis of alcohol use disorder;
- Must be within 10 days of last drink;
- Must have been drinking heavily (criteria dependent upon individual?s age, gender, and BMI) for a consistent period of time;
- Must have a breath alcohol level of 0 at screening;
- Must have a Clinical Institute Withdrawal Assessment (CIWA) score less than 8 (indicating no need for medical detox);
- Must have expressed a desire during their initial screen to reduce the number of drinks they regularly consume
Exclusion Criteria:
- Currently taking any medications for the treatment of psychiatric disorders, including substance use disorders, mood disorders, and psychosis;
- Pregnant, as indicated by a pregnancy test which will be administered at baseline;
- Positive for, sedatives, opiates, cocaine, or amphetamine on drug screen at baseline;
- Meets criteria for psychotic disorder, bipolar disorder, or a major depressive episode
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: MBRP
|
An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.
|
Active Comparator: RP
|
An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Heavy Drinking Days at Baseline
Time Frame: Baseline
|
Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
|
Baseline
|
Heavy Drinking Days at Week 4
Time Frame: Week 4
|
Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
|
Week 4
|
Heavy Drinking Days at Week 8
Time Frame: Week 8
|
Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
|
Week 8
|
Heavy Drinking Days at Week 20
Time Frame: Week 20
|
Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
|
Week 20
|
Heavy Drinking Days at Week 32
Time Frame: Week 32
|
Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
|
Week 32
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ken Hutchison, University of Colorado Denver | Anschutz
Publications and helpful links
General Publications
- Karoly HC, Skrzynski CJ, Moe EN, Bryan AD, Hutchison KE. Exploring relationships between alcohol consumption, inflammation, and brain structure in a heavy drinking sample. Alcohol Clin Exp Res. 2021 Nov;45(11):2256-2270. doi: 10.1111/acer.14712. Epub 2021 Sep 22.
- Karoly HC, Ross JM, Prince MA, Zabelski AE, Hutchison KE. Effects of cannabis use on alcohol consumption in a sample of treatment-engaged heavy drinkers in Colorado. Addiction. 2021 Sep;116(9):2529-2537. doi: 10.1111/add.15407. Epub 2021 Jan 26.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-2550
- R01AA024632 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Use Disorder
-
Washington State UniversityRecruitingNicotine Use Disorder | Alcohol Use Disorder (AUD)United States
-
University of North Carolina, Chapel HillCompletedAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateUnited States
-
Université du Québec à Trois-RivièresCompletedAlcohol Use, Unspecified | Alcohol Use Disorder, MildCanada
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Kaiser PermanenteNORC at the University of Chicago; Agency for Healthcare Research and Quality... and other collaboratorsCompleted
-
Medical University of South CarolinaNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institutes...RecruitingAlcohol Drinking | Substance Use | Alcohol Use Disorder | Drinking, Alcohol | Alcohol Use Disorder (AUD)United States
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Central Institute of Mental Health, MannheimNot yet recruitingAlcohol Use Disorder (AUD)Germany
-
Massachusetts General HospitalMbarara University of Science and TechnologyCompletedAlcohol Use Disorder (AUD)Uganda
-
ITAB - Institute for Advanced Biomedical TechnologiesNot yet recruitingNeurobiological Effects of Transcranial Direct Current Stimulation Treatment in Alcohol Use DisorderAlcohol Dependence | Alcohol-Related Disorders | Substance Use Disorders | Drug Abuse | Mental Disorder | Alcohol Abuse | Alcohol Use Disorder (AUD)
Clinical Trials on Mindfulness-Based Relapse Prevention Therapy
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Conselho Nacional de...CompletedBenzodiazepine DependenceBrazil
-
Alexandria UniversityCompleted
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)CompletedSubstance-Related Disorders | Stress Disorders, Post-TraumaticUnited States
-
Pacific UniversityCompletedPost Traumatic Stress Disorder | Substance Use DisordersUnited States
-
University of WashingtonNational Institute on Drug Abuse (NIDA)CompletedSubstance Use DisordersUnited States
-
University of Southern CaliforniaCompletedSubstance Use | Alcohol Use, Underage | Alcohol Problem DrinkingUnited States
-
University of New MexicoNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol Drinking | Alcoholism | Alcohol IntoxicationUnited States
-
Central Hospital, Nancy, FranceUnknownAddiction | Cannabis Dependence | Cannabis Use
-
Pakistan Institute of Living and LearningRecruitingSubstance Use Disorder (SUD)Pakistan
-
Sara HarbyCompleted